Aurora Cannabis Inc Stock Price, News & Analysis

Aurora Cannabis (NASDAQ: ACB) has launched its first medical cannabis concentrates for patients in the United Kingdom, expanding its global medical cannabis portfolio. The company introduced two proprietary cultivar-specific 1.2g resin cartridges: Sourdough (indica) and Electric Honeydew (sativa).

The inhalable cartridges offer key benefits including exceptional flavor profiles, high potency for consistent dosing, and a user-friendly design for convenient and discreet consumption. The products are manufactured in TGA-GMP certified facilities without additives, ensuring premium quality and safety standards.

This launch follows successful implementations in Canada and Australia, demonstrating Aurora's commitment to expanding patient access to high-quality medical cannabis globally. The products are available nationwide through cannabis retailers, with patients advised to consult their doctors or clinics for more information.

Aurora Cannabis (NASDAQ: ACB) has been recognized on The Globe & Mail's 2025 Report on Business Women Lead Here list for its outstanding executive gender diversity. The company, Canada's largest medical cannabis provider, boasts 43% female representation in its executive leadership team.

The recognition highlights Aurora's commitment to diversity and inclusion, as emphasized by CFO Simona King. In 2022, the company established the Women Empowerment Network (WEN), an employee resource group focused on advancing women's professional development through learning and community engagement opportunities.

This achievement will be featured in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canada's largest medical cannabis company, will participate in the inaugural 2025 Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025. The event, hosted by Artemis Growth Partners within the U.S. Capitol Complex, brings together regulators, Congress members, international policy experts, and cannabis industry executives.

Rick Savone, Senior Vice President of Global Government Relations at Aurora, emphasizes the company's role in advocating for policy reform globally. Aurora will participate in panel discussions focusing on:

• Differences between medical and adult-use cannabis based on international political and regulatory consensus
• How mature medical cannabis markets can guide regulations in emerging markets

Aurora Cannabis (NASDAQ: ACB) has announced a breakthrough discovery of a novel genetic resistance source against powdery mildew, named PM2, at their Aurora Coast research facility. This proprietary genetic marker technology will be implemented in their breeding program to develop resistant cannabis cultivars for potential commercial launch this year.

The research, led by Principal Scientist Jose Celedon in collaboration with The University of British Columbia, aims to enhance biosecurity, reduce production costs, and improve product quality. The discovery has been documented in a peer-reviewed article and protected through international patent filings.

According to Lana Culley, VP of Innovation and International Operations, this development offers a sustainable solution to disease management in cannabis production, particularly where synthetic pesticides are prohibited. The breakthrough reinforces Aurora's commitment to scientific excellence and differentiation in the cannabis industry.

Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis pastille offerings in Australia, introducing three new products: 10mg THC Pomegranate Berry, 10:10 Balanced Pineapple, and 25mg CBD Acai Berry pastilles, each in 30-pack formats.

The expansion demonstrates Aurora's response to growing market demand and strengthens its position as the largest global medical cannabis company in legally operating markets. The pastilles offer several advantages, including easy oral intake, prolonged effects, and a discrete, portable format.

According to Andre Jerome, Executive VP of Global Business Development, this expansion showcases Aurora's understanding of market demand and ability to deliver high-quality products in key markets. The company plans to continue introducing new innovations through its pipeline in the coming months.

Aurora Cannabis (NASDAQ: ACB) has removed the concession card requirement for patients accessing its IndiMed medical cannabis products in Australia, expanding accessibility to all eligible patients in the market. Operating through its wholly-owned subsidiary MedReleaf Australia, this strategic move aims to create more seamless prescribing options in Australia's growing medical cannabis market.

IndiMed, launched in Australia in 2021 as the first concession product, has expanded its portfolio to include oil, dried flower products, and resin cartridges. The brand's flower products consistently rank among the top 10 most prescribed cannabis products for patients. MedReleaf Australia maintains TGA-GMP standards for quality and consistency.

The company has also filed a final short form base shelf prospectus with Canadian provincial securities regulators (except Quebec) and a corresponding shelf registration statement on Form F-10 with the SEC.

Aurora Cannabis (NASDAQ: ACB) has announced a strategic supply agreement with SNDL Inc., expanding their existing partnership. Under the new three-year agreement, valued at $27 million, SNDL will supply Aurora with premium cannabis flower products from their indoor facility in Atholville, New Brunswick.

The agreement includes an extension option and builds upon an existing supply relationship between the two companies for cannabis products and input material manufacturing. Aurora's CEO Miguel Martin emphasized the company's focus on maintaining a hybrid manufacturing network, following their strong third quarter performance driven by record-setting growth in international medical cannabis.

Aurora Cannabis (NASDAQ: ACB) reported strong fiscal Q3 2025 results with total net revenue of $88.2 million, up 37% YoY. The company achieved record-breaking performance across multiple metrics, including global medical cannabis net revenue of $68.1 million (up 51% YoY), net income of $31.2 million (up 282% YoY), and adjusted EBITDA of $23.1 million (up 316% YoY).

The company's international net revenue grew 112% and represented 60% of global medical cannabis revenue. The plant propagation segment increased 22% due to organic expansion. Aurora maintained a strong balance sheet with $180 million in cash and a debt-free cannabis business, except for $57.9 million in non-recourse debt related to Bevo Farms.

Medical cannabis contributed 77% of consolidated net revenue with a 74% adjusted gross margin. Consumer cannabis revenue decreased 15% to $9.9 million as the company prioritized its higher-margin medical cannabis business.

Aurora Cannabis (NASDAQ: ACB) has launched IndiMed, its first German-cultivated medical cannabis brand, manufactured at their EU-GMP facility in Leuna, Germany. This development follows Germany's recent cannabis decriminalization and positions Aurora as one of only three licensed cultivators in the country.

The initial product release is Island Sweet Skunk, a dried flower sativa variant containing 20% THC and <1% CBD, scheduled for availability on January 27. The product is cultivated under GACP and EU-GMP guidelines, featuring hand-harvested flowers that undergo controlled drying and laboratory testing for purity and potency.

As the world's largest medical cannabis company in legal markets, Aurora's expansion in Germany demonstrates its commitment to serving the country's growing patient base with locally produced, high-quality medical cannabis products.